IP Library Granted Patent US 10,792,353
Granted Patent B2
US 10,792,353 · App. 16/213,297 · Granted Oct 6, 2020

Virus like particle purification

Inventors: Thomas S. Vedvick (Cambridge, MA); Bryan Steadman (Cambridge, MA); Charles Richardson (Cambridge, MA); Thomas R. Foubert (Cambridge, MA); Charles R. Petrie (Cambridge, MA)
Assignee: Takeda Vaccines, Inc.
A61K39/12C07K1/18C07K14/005C12N7/00C12N2770/16023C12N2770/16034C12N2770/16051
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,792,353
App. No.
16/213,297
Granted
Oct 6, 2020
Kind
B2
Abstract

Methods for purifying human Calciviruses are disclosed, including Noroviruses and Sapoviruses.

Claims (14)

1. A production method for Norovirus virus-like particles (VLPs), comprising:

transforming insect cells with a baculovirus vector containing a viral nucleic acid sequence encoding a Norovirus major capsid protein VP1;

cultivating the insect cells in a medium thereby expressing the VLPs in the medium;

stopping cultivation when the viability of the insect cells reaches 20% or less; and

isolating supernatant comprising the VLPs from the insect cells thus producing the VLPs.

2. The production method of claim 1 , wherein the Norovirus VLPs are Norovirus genogroup I VLPs.

3. The production method of claim 1 , wherein the Norovirus VLPs are Norovirus genogroup II VLPs.

4. The production method of claim 2 , wherein the Norovirus genogroup I VLPs are Norovirus genotype GI.1.

5. The production method of claim 3 , wherein the Norovirus genogroup II VLPs are Norovirus genotype GII.4.

6. The production method of claim 1 further comprising purifying the Norovirus VLPs.

7. The production method of claim 6 , wherein the purification of the Norovirus VLPs comprises using at least one chromatographic material.

8. The production method of claim 7 , wherein the at least one chromatographic material comprises hydroxyapatite chromatographic material.

9. The production method of claim 8 , wherein the Norovirus VLPs are eluted from the hydroxyapatite chromatographic material using a phosphate buffer.

10. The production method of claim 9 , wherein the phosphate buffer has a concentration of about 1 to about 300 mM.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2019
From: VEDVICK, THOMAS S.; STEADMAN, BRYAN; RICHARDSON, CHARLES; FOUBERT, THOMAS R.; PETRIE, CHARLES R.
To: LIGOCYTE PHARMACEUTICALS, INC.
Reel/Frame 049158/0800 →
MERGER AND CHANGE OF NAME Recorded May 13, 2019
From: TAKEDA VACCINES (MONTANA), INC.; INVIRAGEN, INC.; TAKEDA VACCINES, INC.
To: TAKEDA VACCINES, INC.
Reel/Frame 049158/0823 →
CHANGE OF NAME Recorded May 13, 2019
From: LIGOCYTE PHARMACEUTICALS, INC.
To: TAKEDA VACCINES (MONTANA), INC.
Reel/Frame 049158/0935 →
Continuity (5)
Continuation 15144265 · May 2, 2016
Division 13914331 · Jun 10, 2013
Continuation 12531248
Provisional Application 60906821 · Mar 14, 2007
Related Publication 20190282686A1 · Sep 19, 2019
Cited By (1)
US 12,286,456